Prediction of Response to Pegylated Interferon plus Ribavirin byIL28BGene Variation in Patients Coinfected with HIV and Hepatitis C Virus
Clinical Infectious Diseases2010Vol. 51(7), pp. 788–795
Citations Over TimeTop 1% of 2010 papers
Juan A. Pineda, Antonio Carúz, Antonio Rivero, Karin Neukam, Irene Casanova‐Salas, Ángela Camacho, José-Carlos Palomares-Salas, José Antonio López Mira, Antonio Martínez, Carmen Roldán, Julián de la Torre, Juan Macı́as
Abstract
IL28B gene variations independently predict SVR in HIV/HCV-coinfected patients with HCV genotype 1 and non-genotype 1 HCV infection. The association between rs12979860 and plasma low-density lipoprotein cholesterol suggests that the system low-density lipoprotein ligand/receptor might be involved in the effect of this genotype.
Related Papers
- → Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C(2005)5 cited
- → 576 Early detection of depressive symptoms during treatment with pegylated interferon α-2 and ribavirin in euthymic chronic hepatitis C patients(2006)
- → 907 IS SHORT TIME COMBINED THERAPY WITH PEGYLATED INTERFERON PLUS RIBAVIRIN EFFECTIVE IN PATIENTS WITH ACUTE HEPATITIS C?(2013)
- → Dermatological Side Effects in a Patient with Hepatitis C Infection During Treatment with Pegylated Interferon/Ribavirin+Telaprevir: A Case Report(2014)
- → Pegylated Interferon, Ribavirin, and Sofosbuvir Combination versus Pegylated Interferon, Ribavirin in the Management of Chronic Hepatitis C Egyptian Patients(2017)